Trial Profile

Do healthy males aged 18 years and older show an effect of Bremelanotide on social cognition and behaviour?

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Apr 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bremelanotide (Primary)
Indications Cognition disorders
Focus Therapeutic Use

Most Recent Events

31 Mar 2021 Status changed from recruiting to completed.
31 Mar 2021 Inclusion criteria is updated to increase the minimum age limit from 16 to 18 years.
31 Mar 2021 Planned number of patients changed from 30 to 61.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com